The efficacy and safety of preprandial Neoral once-daily administration for adult patients with Minimal Change Nephrotic Syndrome

The efficacy and safety of preprandial Neoral once-daily administration for adult patients with Minimal Change Nephrotic Syndrome - The efficacy of preprandial Neoral once-daily administration for MCNS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027185

Enrollment

Registered

2017-04-28

Start date

2006-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimal change nephrotic syndrome

Interventions

The initial dosage of steroid was 0.8 mg perkg per day. If the proteinuria decreased to 1 g per day, the initial dosage was maintained for 2 weeks, and then the dosage was reduced to 0.6 mg per kg per

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: They had been admitted to St. Marianna University School of Medicine Hospital from 2007 to 2010 and were subsequently diagnosed with new-onset MCNS by renal biopsy.

Exclusion criteria

Exclusion criteria: Patients with systemic disease, malignant tumors, diabetes, liver disease, or chronic kidney disease (CKD) were excluded from this study.

Design outcomes

Primary

Measure	Time frame
The primary efficacy endpoints were the duration of remission and the relapse rate.	—

Countries

Japan

Contacts

Public ContactSayuri Shirai

St. Marianna University School of Medicine nephrology and hypertension

sirababu@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026